AVLN · Avalyn Pharma Inc.
$27.89
-0.60 (-2.11%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$1.21B
Shares
44.33M
Volume · Oct 1
45.92K
Avg daily vol (3M)
248.47K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$28.49
Open$27.05
Day$26.57–29.00
Available close range$25.68–39.25
Avg vol 30d236K
Short int2.1M · 4.7% float · 9.6d
Short vol88%
Last earningsJun 3, 2026
DataApr 2026–Sep 2026
Filing10-Q · Aug 12
The closing range uses available history since Apr 30, 2026; less than a full year is stored.
Up next
filed Aug 12, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$337.62M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2,488.9%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
4.7%
Latest settlement · 9.6 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Limited
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
−15%
below
RSI (14)
36
neutral
MACD trend
Negative
52-week position
21%
mid-range
Momentum
relative strength
Not enough data for a confident read.
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+93 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.72% of float · ▲ +8.4% MoM · 9.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
93 holders — 13F breadth
Squeeze score
65
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
65%
annualized · 1-yr
Max drawdown
−31%
past year
ATR
7.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
−15%
Bearish
RSI (14)
36
Neutral
MACD trend
Negative
Bearish
52-week position
21%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+93 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.72% of float · ▲ +8.4% MoM · 9.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
93 holders — 13F breadth
Price context
position in its available closing range
Range low $26
Now $28 · 21%
Range high $39
vs 50-day avg -15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents, and marketable securities | $413.5M | Second Quarter 2026 | — |
| Net proceeds from initial public offering | $316.6M | Second Quarter 2026 | — |
| Patients randomized in MIST Phase 2b trial | 398 | Second Quarter 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AVLN
this stock
Avalyn Pharma Inc.
|
$1.21B | — | — | — | 4.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AVLN | -4.0% | -19.3% | — | -18.0% | — |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -3.3% | -19.4% | — | -17.4% | — |